IONS Number of Guru Trades
IONS Volume of Guru Trades
IONS Daily Net ETF Flow
Dollars ETFs put into or pulled out of IONS each day, net of sells, against the share price.
IONS Daily Net ETF Share Flow
Shares ETFs added or removed each day, net, as a share of IONS's shares outstanding, against the share price.
Gurus Latest Trades with NAS:IONS
NAS:IONS is held by these investors
Top ETF Buyers
What each ETF bought and sold in this stock over the period, from the same daily data as the charts above. Sorted by net amount, so sorting ascending brings the heaviest sellers to the top.
ETF Ownership
Every ETF holding the stock, largest position first. Change covers the gap between each fund's last two reports, so a fund that held still shows none.
Guru Commentaries on NAS:IONS
Ionis Pharmaceuticals, a biotechnology company held in three of our four Funds, was another strong contributor following encouraging clinical results that helped renew investor confidence in its research pipeline. This positive momentum indicates a robust outlook for the company, suggesting that its innovative approaches in drug development are gaining traction in the market. The renewed investor confidence reflects the potential for Ionis to capitalize on its research advancements, positioning it favorably within the biotechnology sector.
Ionis Pharmaceuticals is a biotechnology company specializing in RNA-targeted therapies for patients with significant unmet medical needs. The company is transitioning toward commercializing more of its own medicines, allowing it to potentially capture greater long-term value from its innovation. Recent results exceeded expectations, supported by stronger-than-expected commercial performance, while management reaffirmed its expectation of reaching cash flow breakeven in 2028. We continue to see attractive long-term opportunities across the company's commercial portfolio and pipeline.
News about NAS:IONS
Total 0- 1
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
